TreatmentOctober 13, 2021
Biologic Treatment for Moderate-to-Severe Plaque Psoriasis & Navigating Medicare Part B Coverage
Listen to dermatologist and National Psoriasis Foundation Board member, Jerry Bagel, M.D., Director of the Psoriasis Treatment Center of New Jersey, share guidance for older adults on how to manage their moderate-to-severe plaque psoriasis symptoms, provide an overview of ILUMYA® (tildrakizumab-asmn) as a treatment option and discuss how to navigate treatment coverage under Medicare Part B. We will also hear from Nancy about her journey with moderate-to-severe plaque psoriasis.
ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection-site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice about side effects.
This webinar is sponsored by Sun Pharma. For Important Safety Information: https://bit.ly/2We7fIS.